Fred Alger Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Fred Alger Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.79M	Hold	12,597	–	–	0.01%	267
2026 Q1	$4.17M	Buy	+12,597	New	+$4.29M	0.02%	246
2025 Q4	–	Sell	-1,986	Closed	-$906K	–	464
2025 Q3	$906K	Buy	+1,986	New	+$809K	﹤0.01%	373
2020 Q3	–	Sell	-18,558	Closed	-$2.75M	–	463
2020 Q2	$2.75M	Buy	18,558 +1,587	+9%	+$214K	0.01%	287
2020 Q1	$1.85M	Sell	16,971 -6,026	-26%	-$696K	0.01%	281
2019 Q4	$2.65M	Sell	22,997 -568,973	-96%	-$56.7M	0.01%	277
2019 Q3	$47.6M	Sell	591,970 -196,849	-25%	-$15.6M	0.19%	118
2019 Q2	$57.2M	Buy	788,819 +371,106	+89%	+$28.5M	0.22%	106
2019 Q1	$39M	Buy	417,713 +328,635	+369%	+$27.5M	0.16%	130
2018 Q4	$6.5M	Sell	89,078 -40,004	-31%	-$3.08M	0.03%	192
2018 Q3	$11.3M	Buy	129,082 +103,829	+411%	+$10.4M	0.04%	178
2018 Q2	$2.49M	Buy	+25,253	New	+$2.5M	0.01%	271
2014 Q2	–	Sell	-122,969	Closed	-$8.26M	–	623
2014 Q1	$8.26M	Buy	122,969 +42,556	+53%	+$3.29M	0.04%	318
2013 Q4	$5.17M	Buy	+80,413	New	+$4.8M	0.03%	335

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fred Alger Management's ALNY Position: Q2 2026 in Review

Fred Alger Management held its Alnylam Pharmaceuticals (ALNY) position steady in Q2 2026 at 12,597 shares worth $3.79M. The position accounts for 0.01% of the portfolio, ranked #267.

Fred Alger Management first reported a position in ALNY in Q4 2013 and has held it in 14 quarters since. The position peaked at $57.2M in Q2 2019. 785 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

Fred Alger Management held 12,597 shares of Alnylam Pharmaceuticals worth $3.79M as of Q2 2026.
Fred Alger Management left its Alnylam Pharmaceuticals share count unchanged in Q2 2026.
Alnylam Pharmaceuticals made up 0.01% of Fred Alger Management's portfolio in Q2 2026, its #267 holding.
Fred Alger Management first reported a position in Alnylam Pharmaceuticals in Q4 2013 and has held it in 14 quarters since.
Fred Alger Management's Alnylam Pharmaceuticals position peaked at $57.2M in Q2 2019.
785 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Fred Alger Management's 13F filing for Q2 2026, filed 14 Aug 2026.